首页> 外国专利> BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy

BRCA1 mRNA expression predicts survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy

机译:BRCA1 mRNA表达预测新辅助顺铂化疗治疗的膀胱癌患者的生存

摘要

The invention relates to methods for predicting the clinical outcome of a patient which suffers from bladder cancer based on the expression levels of BRCA1 wherein high BRCA1 expression levels are indicative of a poor prognosis. Moreover, the invention relates to methods for predicting the response to chemotherapy of a patient which suffers from bladder cancer based on the expression levels of BRCA1, in particular, in patients which have been treated with chemotherapy prior to surgical removal of the tumor.
机译:本发明涉及基于BRCA1的表达水平预测患有膀胱癌的患者的临床结果的方法,其中高的BRCA1表达水平指示不良的预后。此外,本发明涉及基于BRCA1的表达水平来预测患有膀胱癌的患者对化学疗法的反应的方法,特别是在外科手术切除肿瘤之前已经用化学疗法治疗的患者中。

著录项

  • 公开/公告号AU2009216723A1

    专利类型

  • 公开/公告日2009-08-27

    原文格式PDF

  • 申请/专利权人 PANGAEA BIOTECH S.A.;

    申请/专利号AU20090216723

  • 发明设计人 RAFAEL ROSELL COSTA;MIGUEL TARON ROCA;

    申请日2009-02-20

  • 分类号G01N33/574;C12Q1/68;

  • 国家 AU

  • 入库时间 2022-08-21 19:21:55

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号